Official UK procurement notice
Additional Flu Vaccines for the 21/22 Flu Season
Authority: Department of Health & Social Care (Central government)
What is being bought
Published requirement descriptionThis Contract is for a centrally procured, additional supply of Influenza Vaccine to ensure sufficient supply of flu vaccine for the 21/22 flu season
CPV: Influenza vaccines
The lotProcurement structure
single lot · no lot value publishedLot #1The Department of Health and Social Care is procuring a stock of flu vaccines over and…Awarded
The Department of Health and Social Care is procuring a stock of flu vaccines over and above that which is needed for business as usual. This is in order to increase the uptake of flu vaccines for the 21/22 flu season while the covid-19 pandemic still persists and protect the population against the combined effect of flu and covid-19.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 4 Nov 2021, 17:28 GMT
- Last source update
- 18 Jan 2022, 12:54 GMT
- FTS notice number
2022/S 000-001453- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02f3cdFind a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
The Authority needed to secure additional flu vaccines to supplement business as usual stocks so that it was in a position of being ready to co-administer the Covid-19 booster and flu vaccine simultaneously as this will result in a greater uptake of the flu vaccine to a wider cohort of the population. However the high global demand for flu vaccines and the limited global stocks of these vaccinations gave rise to an extremely urgent need for the Authority to purchase additional flu vaccines for the 2021/22 flu season to maintain security of supply to immunise the population as required and safeguard public health. It was imperative in the face of high global demand, that the Authority moved quickly to secure supply and as such there was insufficient time to comply with the standard Open Procedure time scales for this procurement. Accordingly, the Authority used the negotiated procedure without prior publication – Regulation 32(2)(c) – Extreme Urgency Route (i.e. direct award) permitted under the Public Contract Regulations 2015 (as amended) to conduct this procurement
Publisher note: This Contract is for a centrally procured, additional supply of vaccine from 3 suppliers: 1. Flucelvax TetraQuadrivalent Influenza Vaccine from Seqirus UK Limited at a value of £7,455,000 2. Influvac Tetra QIVe Influenza Vaccine from Viatris UK Healthcare at a value of £10,000,000 3. Supemtek Quadrivalent Influenza Vaccine from Aventis Pharma Ltd T/A Sanofi at a value of £14,110,000; to ensure sufficient supply of flu vaccine for the 21/22flu season
Notice history
2 releases on Find a TenderPublished amendments (1)
1. The titles on the three published supplier contract documents have each been corrected by formal contract change notice to 'Additional Flu Vaccines for the 21/22 Flu Season' 2. The original FTS notice was incorrectly displayed upon publication, the overall value of the three contracts was published against each individual supplier instead of the contract values being separately defined. This co…
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Aventis Pharma Ltd Trading As Sanofi | — | — | Awarded |
| Seqirus UK Ltd | — | — | Awarded |
| Mylan | — | — | Awarded |
Contracts
Contract 027743-2021-1 · Aventis Pharma Ltd Trading As Sanofi
- Signed
- 8 Oct 2021
- Value
- —
- Status
- active
Contract 027743-2021-2 · Seqirus UK Ltd
- Signed
- 8 Oct 2021
- Value
- —
- Status
- active
Contract 027743-2021-3 · Mylan
- Signed
- 8 Oct 2021
- Value
- —
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 3bids | — | — | £31,565,000 – £31,565,000 |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- The High CourtReview body
Bidders & participating suppliers
3 commercial parties on the notice- Aventis Pharma t/a SanofiAwarded supplier
- Seqirus UK LimitedAwarded supplier
- Viatris UK Healthcare LtdAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.